Abstract:Abstract Patients diagnosed with early stage head and neck squamous cell carcinoma (HNSCC) have a high risk of developing second primary tumors (SPT) or recurrence following curative purpose therapy. To prevent these occurrences, several chemoprevention agents have been developed, including 13-cis-retinoid acid (13-cRA). However, results from clinical trials have remained inconclusive and suggest that biomarkers may be needed to select patients who will receive benefit from therapy. The mTOR signaling pathway plays a major role in the regulation of cell growth, cell survival, and apoptosis. We hypothesized that genetic variation in this pathway may serve as prognostic factors for the development of SPT/recurrence and affect response to chemoprevention therapy. We genotyped 137 SNPs from genes within this pathway in 450 HNSCC patients who received 13-cRA or placebo as part of the Retinoid Head and Neck Second Primary Trial. Genotypes were then analyzed for association with risk of SPT/recurrence to identify biomarkers for prognosis and treatment response. Twenty-two genetic loci were significant prognostic factors for SPT/recurrence in the placebo treatment group. Of these, nine were SNPs within the tuberous sclerosis 1 (TSC1) gene and most often resulted in an increased SPT/recurrence risk for the majority of patients carrying the wild-type genotype. Two of these alleles (rs4962225 and rs7035940) were in strong linkage disequilibrium and resulted in a high risk of SPT/recurrence (HR: 1.92, 95% CI: 1.15–3.23) and a significant 18 month survival disadvantage (Log-rank P = 0.026) in those carrying the wild-type genotype. These results indicate that this locus may be a potential target for chemoprevention. Intriguingly, although 13-cRA did not show a reduction in SPT/recurrence risk overall, response to this therapy was significantly different depending on the patient's genetic background for these potential targets. A significant modulation of SPT/recurrence risk in those who received 13-cRA was observed for seven of the prognostic TSC1 SNPs. The majority of the population with the wild-type genotype were conferred the protective effect of 13-cRA, indicating that the high-risk group for SPT/recurrence were being effectively treated by this chemoprevention intervention. Individuals carrying the wild-type genotype for either TSC1 rs4962225 or rs7035940 were at a 43% reduced risk (95% CI: 0.37–0.88). However those who carried at least one variant allele did not receive the benefit of 13-cRA treatment and were at an increased risk (HR: 1.91, 95% CI: 1.10–3.32). These results indicate that genetic variation within the mTOR pathway, particularly TSC1, could potentially be used to better identify patients who are at high-risk of SPT/recurrence and also those who are candidates for chemoprevention therapy based on their favorable genetic background. Citation Information: Cancer Prev Res 2010;3(1 Suppl):B94.

Predictive Biomarkers and Personalized Medicine Genetic Variants in the PI 3 K / PTEN / AKT / mTOR Pathway Predict Head and Neck Cancer Patient Second Primary Tumor / Recurrence Risk and Response to Retinoid Chemoprevention

Abstract B94: Pharmacogenetics of Retinoid Chemoprevention in Head and Neck Cancer Patients: Modulation of Response by Common Genetic Variation in the Mtor Signaling Pathway

Global Assessment of Genetic Variation Influencing Response to Retinoid Chemoprevention in Head and Neck Cancer Patients

Novel Susceptibility Loci for Second Primary Tumors/Recurrence in Head and Neck Cancer Patients: Large-Scale Evaluation of Genetic Variants

Data from Integrative Analysis Identifies a Novel AXL–PI3 Kinase–PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer

Supplementary Table 1 from Genetic Variants in the PI3K/PTEN/AKT/mTOR Pathway Predict Head and Neck Cancer Patient Second Primary Tumor/Recurrence Risk and Response to Retinoid Chemoprevention

Abstract PR-03: Genetic Variations in Microrna Biogenesis Genes As Predictors for Risk of Second Primary Tumor (SPT) And/or Recurrence in Patients with Early-Stage Head and Neck Cancer

Genetic Variants in the Telomere Maintenance Pathway As Predictors of Second Primary Tumors and Recurrence of Early-Stage Head and Neck Cancer

Combination of Radiosensitivity Gene Signature and PD-L1 Status Predicts Clinical Outcome of Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma: A Study Based on the Cancer Genome Atlas Dataset

Prognostic Gene Signature for Squamous Cell Carcinoma with a Higher Risk for Treatment Failure and Accelerated MEK-ERK Pathway Activity

Genetic variations in regulator of G-protein signaling genes as susceptibility loci for second primary tumor/recurrence in head and neck squamous cell carcinoma.

Anti-PD-(L)1-Based Neoadjuvant Therapy in Head and Neck Carcinoma: a Meta-analysis of Prospective Clinical Trials.

MicroRNA-related genetic variations as predictors for risk of second primary tumor and/or recurrence in patients with early-stage head and neck cancer.

Predictive Biomarkers and Personalized Medicine Genetic Variations in Epigenetic Genes Are Predictors of Recurrence in Stage I or II Non – Small Cell Lung Cancer Patients

Genetic Variations in the PI3K/PTEN/AKT/mTOR Pathway Are Associated with Clinical Outcomes in Esophageal Cancer Patients Treated with Chemoradiotherapy

Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy.

PI3K/PTEN/AKT/mTOR Pathway Genetic Variation Predicts Toxicity and Distant Progression in Lung Cancer Patients Receiving Platinum-Based Chemotherapy.

Abstract 1728: Genetic Variations in Epidermal Growth Factor Receptor Pathway Predict Recurrence and Response to Chemotherapy in Early Stage Non-Small Cell Lung Cancer

Tumor Genomics and the Association with Survival in Recurrent/metastatic Head and Neck Cancer Patients

Clinical-genomic determinants of immune checkpoint blockade response in head and neck squamous cell carcinoma

Inflammation-related genetic variations and survival in patients with advanced non-small cell lung cancer receiving first-line chemotherapy.